Sai Life Sciences Launches Peptide Research Center in Hyderabad.

Sai Life Sciences, a leading Contract Research, Development, and Manufacturing Organisation (CRDMO), has established a dedicated Peptide Research Center at its integrated R&D campus in Hyderabad to support the growing demand for complex peptide-based therapeutics.

“As the pharmaceutical industry evolves from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead,” said Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences. “Our new Peptide Research Center reflects this commitment and reinforces our role as a trusted partner in advancing next-generation therapeutics.”

The facility is tailored to assist global pharma and biotech innovators with advanced services in peptide synthesis, discovery, and conjugation. It features automation, high-throughput systems, and robotics, aiming to deliver greater precision, scalability, and efficiency in developing peptide-based drugs.

Maneesh Pingle, Head of Discovery Services, noted the growing demand for peptide therapeutics, citing their specificity, biocompatibility, and reduced risk of off-target effects. “With a seasoned scientific team and expanding capabilities, we are well-positioned to support clients across diverse therapeutic areas,” he said.

The new center will be integrated with Sai Life Sciences’ broader end-to-end discovery platform, which includes synthetic and medicinal chemistry, biology, and toxicology services.

HBL